rexresearch.com
rexresearch1.com
EBOLA // MARBURG VIRUS PATENTS
https://worldwide.espacenet.com/advancedSearch?locale=en_EP
1. METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING EBOLA VIRUS
US2023375547
2. Target sequence of Ebola virus and application thereof
CN117051018
3. Primer probe composition for detecting Ebola virus and integrated micro-fluidic chip kit
CN117004766
4. Application of PAR1 as target for treating or inhibiting Ebola virus
CN116999558
5. Use Of Berbamine Dihydrochloride In Preparation Of Ebola Virus Inhibitor
US2023321079
The present invention provides use of berbamine dihydrochloride in preparation of an Ebola virus inhibitor. In the present invention, the primed glycoprotein of the Ebola virus (EBOV-GPcl) is taken as a target site, and an antiviral active compound with the capability of binding to the EBOV-GPcl, i.e., berbamine dihydrochloride, is obtained through structure-based virtual screening. Berbamine dihydrochloride can specifically inhibit the entry of an Ebola recombinant virus by binding to the target protein EBOV-GPcl, thereby achieving the effect of anti-Ebola virus infection. The half-maximum effect concentration (EC50) of berbamine dihydrochloride against EBOV is 0.49 μM, which indicates that berbamine dihydrochloride has a strong inhibition effect on EBOV.
6. Ebola Virus Antibodies and Binding Agents Derived Therefrom
US2023303667
7. Ebola virus recombinant vaccine and application thereof
CN116751794
8. HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
MY189452
9. Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and Coronavirus
US2023241163
10. Compositions and methods related to ebola virus vaccines
CN116472278
11. Application of Enberic acid or pharmaceutically acceptable salts thereof in preparation of anti-Ebola virus drugs
CN116251082
The invention discloses an application of Enberic acid or a pharmaceutically acceptable salt thereof in preparation of an anti-Ebola virus drug. It is found that the Enberic acid can effectively inhibit growth or reproduction of the Ebola virus, inhibit transcription and replication of the Ebola virus, and inhibit RNA synthesis of the Ebola virus by acting on an active pocket of a binding interface of VP30 protein and NP protein of the Ebola virus in a targeting mode. According to the invention, the application range of the endophytic acid is expanded, and especially under the condition of serious shortage of anti-Ebola virus specific drugs, a new drug and a new treatment mode are provided for inhibiting Ebola virus diseases caused by Ebola viruses.
12. Application of Kobe2602 or pharmaceutically acceptable salt thereof in preparation of anti-Ebola virus drugs
CN116251085
13. PHYSICAL METHODS FOR LIVING TISSUE INACTIVATION AND DETECTION, AND PHYSICAL METHODS IN USE FOR THE DETECTION AND INACTIVATION OF LIVING BODIES (LIKE EBOLA AND 2019 CORONAVIRUS) IN LIVING SYSTEMS AND NON-LIVING SYSTEMS THEREOF
US2023172478
14. ANTIBODIES TO SUDAN AND EBOLA VIRUS
US2023174627
15. BISPECIFIC ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
WO2023201333
16. EBOLA PSEUDOTYPED VECTORS AND METHODS OF USE THEREOF
WO2023064884
17. COMPOSITIONS AND METHODS USEFUL FOR EBOLA VIRUS INFECTION
ZA202201079
18. Application of suramin analogue in preparation of anti-Ebola virus medicine
CN115844865
19. MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS
US2023044044
20. RPA Primer set for recombinase polymerase amplification reaction for detecting Ebola virus and kit comprising the same
KR20220123992
21. Nucleic acid for inhibiting Ebola virus, pharmaceutical composition containing nucleic acid and application of pharmaceutical composition
CN115058425
22. Application of FRAX597 compound in preparation of medicine for treating Ebola virus disease
CN114869889
23. FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION
WO2022165434
24. Application of zinc finger protein ZNF598 as Ebola virus disease treatment target
CN114574491
25. Application of eukaryotic translation initiation factor EIF4B as Ebola virus disease treatment target
CN114470212
26. Application of inhibitor in ceramide synthesis and decomposition pathway in preparation of medicine for treating Ebola virus diseases
CN114452278
27. Application of PLK1 as target spot in preparation of medicine for treating Ebola virus diseases
CN114432454
28. Method and apparatus for real-time diagnostic testing (RDT) of ebola and other infectious diseases
CN114262753
29. EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF
US2022089694
30. METHODS OF USING SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EBOLA VIRUS
US2022089783
31. Cyclic polypeptide for resisting Ebola virus or pharmaceutical salt thereof
CN113999284
32. VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
US2021386849
33. INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA
US2021369754
34. Dominant epitope peptide of Ebola virus envelope glycoprotein as well as coding gene and application thereof
CN113717257
35. EBOLA VACCINE COMPOSITIONS AND METHODS OF USING SAME
US2021340185
36. Anti-Ebola virus monoclonal antibody, and preparation method and application thereof
CN113512111
37. Recombinant virus for expressing Ebola GP protein and preparation method and application of recombinant virus
CN113416714
38. Target LY6E capable of effectively inhibiting Ebola virus infection and application thereof
CN113384700
39. UNIVERSAL INTEGRATION VECTOR pVEAL AND RECOMBINANT PLASMID pVEAL-15742, PROVIDING SYNTHESIS AND SECRETION OF scFv-Fc ANTIBODIES AGAINST EBOLA VIRUS ADI-15742 IN MAMMALIAN CELLS AND OBTAINED USING pVEAL VECTOR
RU2749459
40. EBOLA-ZAIRE VIRUS STRAIN ESMS 2020 ADAPTED FOR GUINEA PIGS, INTENDED FOR PRECLINICAL TESTING OF MEDICAL PROTECTIVE MEANS AGAINST EBOLA HEMORRHAGIC FEVER
RU2749345
41. Antibodies that bind Ebola glycoprotein and uses thereof
AU2021203156
42. KITS FOR PREVENTING AND TREATING EBOLA
US2021161933
43. SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE
US2021163454
44. Preparation and application of Ebola virus infected cell model
CN112824525
45. NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
US2021079067
46. Ebola Virus and Marburg Virus Glycoprotein Mucin-Like Domain Replacement Expression System used as New Vaccine Approaches
US2021069316
47. NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE
EP3875481
48. NUCLEIC ACID ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS
US2021047388
49. RECOMBITANT PLASMID DNA pET21-VP40VE CONTAINING THE GENE FOR THE MATRIX PROTEIN VP40 OF EBOLA VIRUS
RU2742511
50. RECOMBINANT PLASMID DNA PET21-NPVE CONTAINING NUCLEOLOPROTEIN (NP) GENE OF EBOLA VIRUS
RU2739505
51. TARGET APPLICABLE TO THE TREATMENT OF EBOLA VIRUS DISEASE
WO2020237909
52. EBOLA VIRUS TREATING AGENTS
JP2020172497
53. Universal Ebola virus disease immunoglobulin as well as preparation method and application thereof
CN111518815
54. HUMANIZED ANTI-EBOLA VIRUS GLYCOPROTEIN ANTIBODIES AND METHODS OF USE
HK1250723
55. MONOCLONAL ANTIBODIES FOR EBOLA AND MARBURG VIRUSES
CA3081694
56. DNA ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS
US2020216519
57. Nucleic acid for inhibiting Ebola virus, pharmaceutical composition containing nucleic acid, and use of nucleic acid and pharmaceutical composition
CN111378656
58. ANTIBODY-MEDIATED NEUTRALIZATION OF EBOLA VIRUSES
US2020200749
59. METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION
US2020188404
60. MIXTURES OF IMMUNOGENIC CD8 T EPITOPES OF THE EBOLA VIRUS
WO2020245433
61. Primers and probes for simultaneous detection of subtypes of Ebola virus and detecting method for ebola virus using the same
KR20200056346
62. Application of TMED2 as treatment target spot of Ebola viral disease
CN111214663
63. MONOCLONAL ANTIBODY 2G1 FOR BROAD-SPECTRUM NEUTRALIZATION OF EBOLA VIRUSES AND APPLICATION THEREOF
WO2020093672
64. Monoclonal antibody 5A8 specifically bond to Ebola virus glycoprotein glycan cap
CN111138528
65. Monoclonal antibody 4F1 capable of resisting Ebola virus glycoprotein GP1 subunit, and application of monoclonal antibody 4F1
CN111138527
66. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS SUCH AS INFLUENZA AND EBOLA
CA3073815
67. ARTIFICIAL GENES CODING EV.CTL AND EV.Th PROTEINS-IMMUNOGENS... CONTAINING EPITOPES OF EBOLA VIRUS ANTIGENS, USED TO CREATE AN EBOLA VIRUS VACCINE
RU2713723
68. Ebola virus inactivation, disinfection and cleaning device
CN210044528
69. ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN
EP3911414
70. THE EBOLA VIRUS GLYCOPROTEIN AS A TOOL TO STIMULATE AN IMMUNE RESPONSE
WO2020010474
71. IMMUNOGENIC PEPTIDES DERIVED FROM THE NUCLEOPROTEIN OF THE EBOLA ZAIRE VIRUS
WO2020144355
72. crRNA target point and CRISPR-Cas13a system for detecting Ebola virus
CN110628955
73. Primer group, composition and kit for detecting Ebola virus
CN110499392
74. MONOCLONAL ANTIBODY SPECIFIC FOR EBOLA VIRUS
RU2705763
75. Selection and optimization of aptamers to recognize ebola markers
US2019310252
76. DNA ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS
US2019290750
77. PHARMACEUTICAL COMPOSITIONS FOR TREATING EBOLA VIRUS DISEASE
US2019282601
78. EBOLA VIRUS VACCINE
US2019276495
79. METHOD OF USE OF ERITORAN AS A TLR4 ANTAGONIST FOR TREATMENT OF EBOLA AND MARBURG DISEASE
US2019275067
80. MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS
US2019263894
81. HYDROCHLORIDE 1,7,7-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-YL 3-(PIPERIDIN-1-YL)PROPIONATE USED AS AN EBOLA VIRUS INHIBITOR
RU2697716
82. N- C- NC N-TERMINUS DOMAIN FRAGMENTS C-TERMINUS DOMAIN FRAGMENTS AND NC FUSION PROTEIN OF EBOLA VIRUS NUCLEOPROTEIN KIT FOR DIAGNOSING EBOLA VIRUS INFECTION USING THEREOF
KR102006869
83. MONOCLONAL ANTIBODY COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS
US2019247501
84. NOVEL HUMANIZED ANTI-EBOLA ANTIBODIES USEFUL IN PREVENTING EBOLA INFECTIONS
US2019240328
85. Ebola virus entry inhibitor composition and application thereof
CN109939233
86. ANTIVIRAL POLYCLONAL ANTIBODIES AGAINST EBOLA VIRUS AND THE USES THEREOF
US2019185548
87. STRAINS OF HYBRID CELLS OF ANIMALS MUS_ MUSCULUS - PRODUCERS OF MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE) AND MONOCLONAL ANTIBODIES TO PROTEIN GP OF EBOLA VIRUS (SUBTYPE ZAIRE)
RU2686630
88. Application of telithromycin in anti-ebola-virus infection
CN109700823
89. CYTOMEGALOVIRUS-BASED VACCINE EXPRESSING EBOLA VIRUS GLYCOPROTEIN.
MX2017009889
90. Compositions and Methods for Generating an Immune Response to a Hemorrhagic Fever Virus
US2019117758
91. Small-molecule synthetic compound 1712 anti-ebola virus activity screening method
CN109486899
92. METHOD FOR PRODUCING LIQUID IMMUNOGLOBULIN AGAINST EBOLA FEVER FROM HORSE BLOOD SERUM
RU2673546
93. USE OF TEICOPLANIN AGAINST EBOLA VIRUS
US2018353568
94. Ebola virus small molecular inhibitor
CN108853075
95. RECOMBINANT ANTIBODIES THAT RECONGNIZE THE C-TERMINAL DOMAINS OF EBOLA VIRUS NUCLEOPROTEIN
US2018334494
96. Ebola Virus Disease Vaccine Taking Human Replication Deficient Adenovirus As Vector
US2018264100
97. Anti-Ebola virus VP40 protein monoclonal antibody A2G7 and application thereof
CN108484758
98. EBOLA/MARBURG VACCINES
US2018243225
99. MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS
EP3583122
100. MONOCLONAL ANTIBODY NEUTRALIZING INFECTIVITY OF ALL EBOLA VIRUSES
US2018237503
101. PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILS
US2018237502
102. RNA INTERFERENCE THERAPEUTICS AGAINST EBOLA VIRUS
US2018235995
103. Anti-Ebola virus VP40 protein monoclonal antibody F1B4 and application thereof
CN108424448
104. Preparation and application of thermal-stability ebola therapeutic antibody
CN108373500
105. Gene engineering bacterium for preparing Ebola virus nucleoprotein antigen and application
CN108342348
106. Ebola virus resisting VP40 protein monoclonal antibody G7A6 and application thereof
CN108250293
107. Ebola virus typing detection primer, probe and kit
CN108165669
108. Small molecule inhibitor of Ebola pseudovirus
CN108014102
109. Zaire type ebola virus detection antibody as well as preparation method and application thereof
CN108017715
110. Inhibitor for Ebola virus
CN107789344
111. HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF
EP3351628
112. Chimpanzee adenovirus vector based Ebola virus vaccine
CN107753941
113. METHODS AND REAGENTS FOR DETECTING EBOLA VIRUS
US2018044741
114. Ebola virus composition/vaccine
US9889188
115. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EBOLA VIRUS DISEASE
US2018021333
116. Traditional Chinese medicine compound extract for preventing and treating EBV (Ebola Virus) infection and preparation method thereof
CN107551227
117. Applications of glycyrrhetinic acid in preparing medicines for resisting ebola virus
CN107550916
118. Anti-Ebola virus GP protein monoclonal antibody, and applications thereof
CN107541522
119. ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTION
US2018016322
120. Methods and compositions for Ebola virus vaccination
CN107530383
121. PRIMER SET FOR DETECTION OF ZAIRE EBOLA VIRUS, ASSAY KIT, AND AMPLIFICATION METHOD
US2017369940
122. Anti-Ebola virus neutralizing monoclonal antibody
CN107417788
123. NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS
US2017334973
124. IMMUNOGEN PEPTIDES AND "EPIVAKEBOL" VACCINE AGAINST EBOLA FEVER WITH APPLICATION OF INDICATED PEPTIDES
RU2635998
125. MONOCLONAL ANTIBODY COCKTAIL FOR TREATMENT OF EBOLA INFECTIONS
WO2017192483
126. Triterpene derivative and application thereof in resistance to Ebola virus
CN107304221
127. Application of semen coicis extract in anti-Ebola virus
CN107296905
Application of Coix Seed Extract in Anti-Ebola Virus -- As a traditional Chinese medicine, coix seed is the mature seed kernel of the gramineous herbaceous plant Coix and contains a variety of biologically active substances.
Since the 1960s, Chinese and foreign scholars have successively reported the pharmacological activities of coix seed in anti-tumor, immune regulation, lowering blood sugar and blood calcium, lowering blood pressure, anti-virus, inhibiting trypsin, and inducing ovulation. The research focus mainly focuses on the extraction of coix seed or the application of its active ingredients in anti-tumor. Injections with coix seed oil as the active ingredient have been used in the clinical treatment of primary liver cancer and non-small cell lung cancer for many years. Reports on its antiviral effects are basically based on the combination of coix seed and other multi-flavored Chinese herbal medicines. In terms of single use, only Zhang Yumei et al. mentioned in the article "Research Progress on the Chemical Composition and Pharmacological Activity of Coix Seed" that methanol extract of Coix Seed has strong inhibitory activity on the activation of Epstein-Barr virus early antigen (EBVEA), and isolated An antiviral active ingredient, α-monolinolenate (Chinese Pharmaceutical Journal, Volume 37, Issue 1, January 2002, Pages 8-11). In addition, there is no research on coix seed or its active ingredients being used alone for antiviral research, not to mention that there is no effective vaccine or treatment for Ebola, which has a complex pathogenic mechanism, high mortality, and low cure rate. There is no record of viruses.
[0007]
The inventor has devoted many years to the medicinal research of coix seed, and the coix seed extract, especially the coix seed extract obtained by the method of the present invention, can significantly inhibit Ebola virus within a certain dose range...
Application of Coix Seed Extract in Anti-Ebola Virus
....As a traditional Chinese medicine, coix seed is the mature seed kernel of the gramineous herbaceous plant Coix and contains a variety of biologically active substances.
Since the 1960s, Chinese and foreign scholars have successively reported the pharmacological activities of coix seed in anti-tumor, immune regulation, lowering blood sugar and blood calcium, lowering blood pressure, anti-virus, inhibiting trypsin, and inducing ovulation. The research focus mainly focuses on the extraction of coix seed or the application of its active ingredients in anti-tumor. Injections with coix seed oil as the active ingredient have been used in the clinical treatment of primary liver cancer and non-small cell lung cancer for many years. Reports on its antiviral effects are basically based on the combination of coix seed and other multi-flavored Chinese herbal medicines. In terms of single use, only Zhang Yumei et al. mentioned in the article "Research Progress on the Chemical Composition and Pharmacological Activity of Coix Seed" that methanol extract of Coix Seed has strong inhibitory activity on the activation of Epstein-Barr virus early antigen (EBVEA), and isolated An antiviral active ingredient, α-monolinolenate (Chinese Pharmaceutical Journal, Volume 37, Issue 1, January 2002, Pages 8-11). In addition, there is no research on coix seed or its active ingredients being used alone for antiviral research, not to mention that there is no effective vaccine or treatment for Ebola, which has a complex pathogenic mechanism, high mortality, and low cure rate. There is no record of viruses.
The inventor has devoted many years to the medicinal research of coix seed, and the coix seed extract, especially the coix seed extract obtained by the method of the present invention, can significantly inhibit Ebola virus within a certain dose range.
The present invention also aims to provide an anti-Ebola virus method, which includes: administering an effective amount of coix seed extract to a mammal in need of treatment.
Among them, the effective dose of coix seed extract is: 50-200ml/day/person.
The Ebola virus includes confirmed and unidentified subtypes, among which the confirmed subtypes are: EBO-Zaire, EBO-Sudan , Ebola-Reston type (EBO-R) and Ebola-Ivory Coast type (EBO-CI).
The coix seed extract can be made into tablets, capsules, capsules, granules or injections.
The above preparation specifically includes the coix seed extract of the present invention and one or several pharmaceutically acceptable carriers.
Wherein, the pharmaceutically acceptable carrier includes conventional diluents, excipients, fillers, emulsifiers, adhesives, lubricants, absorption accelerators, surfactants, disintegrants or antioxidants in the pharmaceutical field, Flavoring agents, sweeteners, preservatives or coloring agents can also be added if necessary.
The pharmaceutically acceptable carrier can be selected from: mannitol, sorbitol, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, soybean lecithin, vitamin C, vitamin E , disodium EDTA, calcium sodium EDTA, monovalent alkali metal carbonates, acetates, phosphates or their aqueous solutions, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acids, sodium chloride, potassium chloride, sodium lactate, hydroxybenzene Ethyl ester solution, benzoic acid, potassium sorbate, chlorhexidine acetate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and its Derivatives, alginate, gelatin, polyvinylpyrrolidone, glycerin, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, β-cyclodextrin, phospholipid materials , kaolin, talc, calcium stearate or magnesium stearate.
The coix seed extract is prepared according to the following method:
Supercritical carbon dioxide extraction: Grind the coix seed into 10 to 50 mesh, use a supercritical CO2 extractor to extract, put the coix seed powder into the extraction kettle, and use jacketed circulating hot water to heat the CO2 preheater, extraction kettle and separation column , make the extraction temperature and separation temperature reach 33~45℃ and 30~45℃ respectively, keep the outlet temperature of the first-level analytical kettle and the second-level analytical kettle at 20~50℃ and 15~35℃ respectively; the liquid CO2 flow rate is according to the extracted coix. Coix kernel powder mass is measured, and is pressurized into the CO2 preheater through a high-pressure pump at a flow rate of 2.5kg~7.5kg/h·kg. It becomes a fluid in a supercritical state and enters the extraction kettle, maintaining the pressure at 19~23Mpa to extract coix seed oil. ; The CO2 fluid dissolved with coix seed oil enters the separation column, and the pressure of the separation column is controlled to 7 to 10Mpa to separate the coix seed oil; the CO2 gas coming out of the separation column enters the primary and secondary analysis kettles successively, keeping the pressure at 5 to 5 MPa respectively. 7Mpa and 4~6Mpa, discard the water and other impurities obtained by analysis, and the CO2 gas turns into liquid CO2 through the condenser, which is recycled and continuously extracted for 2~3 hours.
Preferably, the above preparation method also includes a refining step, that is, dissolving petroleum ether, washing with water, decolorizing, washing with water again, alumina treatment and then filtration.
The refining steps are specifically:
Add the crude oil obtained by carbon dioxide extraction into the process tank, take a sample to detect the acid value, then add petroleum ether and about 2% NaOH, raise the temperature to 30-40°C, mix for 15-20 minutes, and let it stand for at least 20 hours; discard the bottom layer. Add purified water twice for washing. The resting time after the first washing is not less than 22 hours, and the resting time after the second washing is not less than 46 hours. Discard the waste; add acetone to break the emulsion and let the emulsion stand. Leave for 3 hours, discard the bottom layer, and obtain "dissolved coix seed oil"; add heat-activated alumina to dehydrate, stir for more than 30 minutes, and then filter to obtain "dehydrated coix seed oil"; add heat-activated alumina to the dehydrated and dissolved oil. Kaolin is decolorized at a decolorization temperature of 41 to 47°C for 30 to 35 minutes, then the temperature is raised to 60 to 65°C under vacuum conditions to remove the solvent; purified water at 60 to 65°C is added, stirred for 20 to 30 minutes, and left to stand for at least 1 hour. Then discard the lower wastewater, heat and dehydrate, the operating conditions are 100~115℃, the vacuum degree is ≥0.094MPa, the processing time is not less than 70 minutes, and the "refined coix seed oil" is obtained; the refined oil is transferred to a stainless steel barrel, and the oil weight is added 10% activated alumina, stored at 2 to 10°C; the oil/alumina mixture is filtered with a set of primary filters containing three 20μ filters, and then filtered through a 0.2μ filter to remove alumina; after filtration, the oil Heating at 165±5℃ for 2 hours; cooling to 60~80℃, final filtration through a 0.2μ filter, then bottling and sealing.
128. EBOLA SPECIFIC CELL PENETRABLE ANTIBODIES
WO2017180069
129. HSOBIENS-WT/GIN/2015/KALIDIE-KINDIA-1022 STRAIN OF EBOLA ZAIRE...
RU2631937
130. METHOD FOR PRODUCTION OF HYPERIMMUNE SERUM CONTAINING HETEROLOGIC IMMUNOGLOBULINES AGAINST EBOLA FEVER
RU2627631
131. METHOD FOR INHIBITING EBOLA VIRUS VIA MIRNA
US2017240898
132. Compositions Comprising Small Interfering RNA Molecules for Prevention and Treatment of Ebola Virus Disease
US2017233742
133. Preparation method of fusion mutant of Ebola virus glycoprotein and matrix protein
CN107034225
134. Monoclonal antibody of human anti-Ebola virus envelope glycoprotein, and application thereof
CN107033242
135. Application of LSECtin as target for treating and/or preventing Ebola virus
CN107019703
136. Fluorescent constant-temperature detection kit for rapidly detecting Ebola viruses
CN106967846
137. MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT
RU2015157143
138. MONOCLONAL ANTIBODY, BINDING WITH EBOLA VIRUS GLYCOPROTEIN, DNA FRAGMENTS CODING THIS ANTIBODY, AND ANTIGEN-BINDING FRAGMENT
RU2015157142
139. Method used for preparing trimer Ebola virus glycoprotein mutant using yeast
CN106868025
140. Toremifene citrate nano suspension, toremifene citrate tablet for treating ebola and preparation methods thereof
CN106821976
141. EBOLA MONOCLONAL ANTIBODIES
US2017183396
142. SINGLE-DOMAIN ANTIBODIES TO EBOLA VIRUS GP PROTEIN FOR IMMUNOTHERAPY OF EBOLA FEVER
RU2015152866
143. Fluorescent quantitative PCR (Polymerase Chain Reaction) kit for detecting Zaire Ebola virus
CN106755600
144. Traditional Chinese medicine tea bag for preventing and treating Ebola virus and preparation method of traditional Chinese medicine tea bag
CN106692595
145. Novel in-vitro and in-vivo infection model based on Ebola virus-like particles
CN106636014
146. Characteristic miRNAs in Ebola virus infected blood and application of characteristic miRNAs
CN106636464
147. DUAL-ACTION VACCINES (DAV) TO PREVENT HIV AND EBOLA VIRUS INFECTIONS
WO2017088053
148. POTENT GLYCOPROTEIN ANTIBODY AS A THERAPEUTIC AGAINST EBOLA VIRUS
US2017121391
149. Molecular markers related to Ebola-hemorrhagic-fever clinical prognosis and application
CN106591445
150. Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis
CN106591446
151. Purifying method and application of ebola-virus antigenic protein
CN106589078
152. Application of statin compounds in blocking of Ebola virus invasion infection
CN106563127
153. Applications of cardiac glycoside compound in resisting Ebola virus infection
CN106562982
154. Marker genes related with Ebola virus infection and applications thereof
CN106544441
155. Primer set for diagnosing Ebola virus and uses thereof
KR20170019927
156. Application of triparanol to resisting Ebola virus infection
CN106361735
157. EBOLA VACCINE
WO2017015457
158. Ebola virus replicon model applicable to antiviral medicine screening and application thereof
CN106318910
159. Methods for the treatment and prevention of Ebola
GB2562691
160. Ebola pseudovirus small molecule inhibitor
CN106265614
161. Samarium- gadolinium- or yttrium-modified superparamagnetic particles for use in Ebola virus detection
CZ2015349
162. Nanometer antibody for neutralizing Ebola viruses
CN106188286
163. COMPOSITIONS AND METHODS FOR THE TREATMENT OF EBOLA VIRUS DISEASE
WO2016181214
164. Development of a Surveillance Methodology using a ebola hemorrhagic fever
KR20160115335
165. MANAGING EBOLA VIRAL INFECTIONS
WO2016172205
166. IMMUNOBIOLOGICAL AGENT AND UTILIZATION METHOD THEREOF FOR INDUCING SPECIFIC IMMUNITY AGAINST EBOLA VIRUS (VARIANTS)
WO2016159823
167. COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION
US2016264971
]168. Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
US2016264972
169. RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA AND EBOLA
WO2016133560
170. HUMANIZED EBOLA ANTIBODIES AND USES THEREOF
WO2016131128
171. 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION
US2016237106
172. IMMUNOBIOLOGICAL DRUG AND METHOD FOR USING SAME FOR INDUCING SPECIFIC IMMUNITY AGAINST THE EBOLA VIRUS
WO2016130047
173. Quantitative RT-PCR detection kit for ebola virus nucleic acid through one-step method
CN105779647
174. LAMP kit for detecting Ebola virus and dedicated primer thereof
CN105779645
175. POLYCLONAL ANTIBODIES FOR USE IN THE PREVENTION AND/OR TREATMENT OF EBOLA VIRUS DISEASE
EP3254691
176. Application of tebufenpyrad structure containing compound to preparation of Ebola virus infection resisting medicines
CN105663123
177. Application of compound containing Merochlorin A structure in preparation of medicines of resisting ebola virus infection
CN105726525
178. PRIMER SET FOR DETECTION OF ZAIRE EBOLA VIRUS, ASSAY KIT, AND AMPLIFICATION METHOD
WO2016098892
179. METHOD OF INHIBITING INFECTIOUS ACTIVITY OF EBOLA VIRUS IN EXPERIMENT
RU2585695
180. IMMUNE MODULATION BY TLR ACTIVATION FOR TREATMENT OF FILOVIRUS INFECTIONS INCLUDING EBOLA
US2016151469
181. PRIMERS, PROBES AND KIT FOR DETECTING AND TYPING FIVE EBOLA VIRUS SUBTYPES BY ONE-STEP METHOD REVERSE TRANSCRIPTION PCR
WO2016078215
182. SYSTEM AND METHOD FOR EBOLA DETECTION
US2016146838
183. PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF EBOLA VIRUS
US2016145698
184. Method for identification of a virus within the filoviruses, allowing for differentiation of different species of EBOLA type
PL410060
185. METHOD OF MEDICALLY TREATING EBOLA AND OTHER ORGANISMS
US2016136201
186. RAMAN SPECTRUM DETECTION METHOD FOR EBOLA VIRUS, AND EBOLA VIRUS ANTIBODY-IMMOBILIZED PLATE
JP2016080565
187. Preparing method and application of soluble Ebola virus envelope protein vaccine
CN105582532
188. COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS EXPRESSION
WO2016071857
189. METHODS OF DETECTING EBOLA
US2016122834
190. METHOD FOR INACTIVATING VIRUS BY EXCHANGING AND REPLACING ANODE ELECTRONS (+IONS) CHARGING THE SURFACES OF VIRUSES AND CATHODE ELECTRONS (-IONS) OF ZEOLITE AND ION-EXCHANGE RESIN SO AS TO INACTIVATE VARIOUS VIRUSES SUCH AS EBOLA VIRUSES, HIV OR IFV (AS WILL BE ABBREVIATED INTO VIRUS)
JP2016063805
191. Method for preventing infections and/or infestations with communicable diseases, and/or treatment of communicable diseases, preferably the Ebola type viral diseases and material for execution of the method described above
PL409916
192. Molecular evolution analysis method of GP gene of Ebola virus
CN105488356
193. IMMUNE-MODIFYING PARTICLES FOR THE TREATMENT OF EBOLA VIRUS
WO2016057909
194. Preparation method and application of recombinant yellow fever viruses for expression of Ebola GP proteins
CN105441395
195. RPA kit used for detecting Ebola virus, and special-purpose primers, probes, and applications of RPA kit
CN105400904
196. HOMEOPATHIC PREPARATION APPLICABLE TO EBOLA VIRUS DISEASE
WO2016037245
197. Therapy and Cure of Ebola
US2016058787
... the first step is providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm. A pharmaceutically effective dose of the NSPS is administered to a patient infected with the pathogen....
198. Ebola virus pollutes space last degassing unit eventually
CN205019465
199. Application of neokadsuranic acid A to preparation of Ebola virus resistant medicine
CN105311034
200. Small Molecule Inhibitors of Ebola and Lassa Fever Viruses and Methods of Use
US2016024066
201. Horse anti-EBOV (Ebola virus) immune globulin F (ab')2 and preparation method thereof
CN105254755
202. METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA, EBOLA...
US2015376584
203. ANTIBODIES THAT NEUTRALIZE EBOLA VIRUS AND USES THEREOF
WO2016075546
204. Lipid Formulated Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus
US2015353934
205. Hybridoma cell strain ZJED0-02, anti-Ebola virus GP (glycoprotein) monoclonal antibody and their preparation and application
CN105112375
206. Method, reagent, primer and probe for quickly detecting Ebola viruses under constant-temperature and isothermal conditions
CN105087825
207. Hybridoma cell strain ZJEB8-01, Ebola-virus GP albumen resistant monoclonal antibody, and preparation and application of Ebola-virus GP albumen resistant monoclonal antibody
CN105087497
208. Biological preparation and application of same in preparation of drugs used for preventing and controlling Ebola virus
CN105031623
209. METHODS OF DETECTING EBOLA
WO2016069853
210. PEPTIDE FOR ANTI-EBOLA VACCINE
WO2016059517
211. SMALL NUCLEIC ACID MOLECULE, DNA MOLECULE AND PROTEIN FOR PREVENTING AND/OR TREATING EBOLA VIRAL HEMORRHAGIC FEVER AND USE THEREOF
WO2015143958
212. Depressant of ebola virus
CN104922284
213. Application of teicoplanin to resisting Ebola virus
CN104873954
214. An anti-Ebola-virus immunoglobulin F(ab')2 and a preparing method thereof
CN104829710
215. TREATMENT OF EBOLA THROUGH ELECTROMAGNETICALLY CHEMICAL INFUSION, USING A NEWLY ADAPTIVE LANGUAGE OF BIO-SIGNALING CELLULAR COMMUNICATIONS
WO2016097830
216. IMMUNOGENIC PEPTIDES OF EBOLA AND APPLICATIONS THEREOF
EP3142693
217. Ebola virus typing fluorescence PCR detection kit
CN104711370
218. Prevention and treatment machine capable of instantly killing ebola and novel viruses by employing thermal radiation of waveguide resonant cavity
CN104667311
219. RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA AND EBOLA
US2015157689
220. Preparation method of pure chlorine dioxide solution and method for treating Ebola virus infection
CN104586880
The invention discloses a preparation method of the pure chlorine dioxide solution,... If the method for treating Ebola virus infection is allowed to be used in the human body and especially in subhealth people, through regular human body disinfection 1-2 times every year, the method can prevent cancer incidence.
221. Ebola virus Reston subtype real-time fluorescence quantitative PCR detection primer pair and kit
CN104561321
222. Medicament for treating Ebola virus and preparation method of medicament
CN104491833
223. Immunochromatography detection strip for rapidly diagnosing Ebola virus infection by one-step method
CN104459122
224. Preparation method for anti-Ebola virus medicine BCX4430
CN104513249
225. Standard sample with molecular characteristics of nucleic acid of Ebola viruses and preparation method thereof
CN104357581
226. Kit for rapidly detecting Ebola virus and application method thereof
CN104328224
227. Kit for rapid typing identification detection on Ebola viruses
CN104328216
228. Isothermal amplification detection kit and detection method for Zaire type Ebola virus
CN104313179
229. Quintuple fluorescent PCR (polymerase chain reaction) rapid hypersensitive detection kit for Ebola and application thereof
CN104212914
230. CONSERVED B CELL EPITOPES OF FILOVIRUS GLYCOPROTEIN AND THEIR USE AS EITHER BIOMARKERS OR THERAPEUTICS...
WO2016079572
231. Small Molecule Inhibitors of Ebola and Lassa Fever Viruses
US2014329834
232. Blood perfusion device special for adsorbing 'Ebola' filoviruses
CN104096278
233. COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION
US2014255444
234. Antigen fragment and truncation based on ebola virus envelope protein as well as application
CN103864904
235. EBOLA VIRUS LIPOSOME VACCINE
JP2014005205
236. SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENT-MARKED PROBES FOR TYPE-SPECIFIC EXPRESS IDENTIFICATION OF EBOLA-ZAIRE VIRUS BY METHOD OF POLYMERASE CHAIN REACTION
RU2487942
237. SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENT-LABELED PROBES FOR SPECIES-SPECIFIC EXPRESS-IDENTIFICATION OF VIRUS EBOLA-SUDAN ...
RU2487167
238. CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES
US2013101618
239. Fluorescent quantitative PCR (polymerase chain reaction) method, primer and kit for detecting EBOV (Ebola virus)
CN103045755
240. One-step process real-time fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction) method and kit for detecting Z/S subtype ebola viruses
CN103045754
241. Multiplex fluorescent polymerase chain reaction (PCR) kit and primers for detecting Ebola viruses...
CN102719557
242. MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS
US2012164153
243. EARLY DIAGNOSTIC TECHNIQUE FOR EBOLA HEMORRHAGIC FEVER IN INDIVIDUALS PRESUMABLY INFECTED WITH SUCH VIRUS
RU2450274
244. OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND OTHER VIRUSES
US2012156239
245. Marburg and Ebola dual-virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system
CN102140533
246. Novel Ebola virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system
CN102140532
247. Cobalt Hexammine as a Potential Therapeutic Against HIV and/or Ebola Virus
US2011027388
...Preparation of Co(III) Hexammine
[0033] While Cohex is available commercially, its synthesis is fairly straight forward, using air to oxidize Co(II) to Co(III):
CoCl2+4NH4Cl+20NH3+O2→4[Co(NH3)6]Cl3+2H2O
9.6 g of CoCl2.6H2O (0.06 mol) and 6.4 g of NH4Cl (0.12 mol) were added to 40 ml of water in a 250 ml Erlenmeyer flask with a side arm and shaken until most of the salts are dissolved. Then 1 g of fresh activated decolorizing charcoal and 20 ml concentrated ammonia were added. Next the flask was connected to the aspirator or vacuum line and air drawn through the mixture until the red solution becomes yellowish brown (usually 2-3 hours). The air inlet tube if preferably of fairly large bore ( ̃10 mm) to prevent clogging with the precipitated Co(NH3)6<3+> salt.
The crystals and charcoal were filtered on a Buchner funnel and then a solution of 6 ml of concentrated HCl in 75 ml of water was added. The mixture was heated on a hot plate to effect complete solution and filtered while hot. The hexamminecobalt (III) chloride was crystallized by cooling to 0° C. and by slowly adding 15 ml of concentrated HCl. The crystals were filtered, washed with 60% and then with 95% ethanol, and dried at 80-100° C...
Cohex Animal Study Against Ebola
An efficacy study was conducted in mice to test whether Cohex would have a therapeutic affect against Ebola virus exposure. Initially, to determine whether the mice would tolerate the Cohex, they received intraperitoneal (IP) injections of Cohex once a day for 10 days at levels of 0.5, 1, 2, 4, and 8 mg/kg in this study. The mice tolerated the compound very well, with no adverse reactions reported.
To examine the efficacy of Cohex, mice were treated by IP injection with either phosphate buffered saline (PBS) or Cohex in PBS one hour before virus exposure, and further treated once a day for 9 more days. In comparing the results of the mice treated with PBS versus those treated with 8 mg/kg of Cohex, it was found to be statistically very likely (p=0.01 in a chi-squared test) that the 8 mg/kg treatment improved survival rates over the PBS treatment in mice infected with Ebola virus...
The general advantages of a broad-spectrum drug, such as Cohex, are its low-cost, stability, and, of course, ability to attack multiple microorganisms. When there is no treatment available, as in the case of Ebola virus, Cohex could be the only source of treatment. For viruses, such as HIV, where drugs with very high TI already exist, Cohex can be used in a combination drug therapy regime. There are several advantages to doing this: (1) as a broad-spectrum compound, Cohex can fight against opportunistic infections by other microorganisms; (2) Cohex may have a synergistic effect on existing anti-HIV drugs; (3) Cohex can significantly decrease the cost of anti-HIV treatment; (4) Cohex can slow the development of viral drug-resistance by presenting a very different mechanism that must be overcome.
248. STRAIN OF HYBRID ANIMAL CELLS Mus musculus L - PRODUCER OF MONOCLONAL ANTIBODIES FOR EXPOSING VP40 PROTEIN OF EBOLA VIRUS...
RU2395577
249. STRAIN OF HYBRID ANIMAL CELLS Mus museums L - PRODUCER OF MONOCLONAL ANTIBODIES FOR EXPOSING NUCLEOPROTEIN OF EBOLA VIRUS...
RU2395576
250. METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES
US2010047282
251. IMMUNOGENIC COMPOSITIONS AND VACCINES FOR EBOLA
US2010034843
252. Optimized vaccines to provide protection against Ebola and other viruses
ZA200703260
253. Ebola viron proteins expressed from venezuelan equine encephalitis (Vee) virus replicons.
AP1944
254. New pharmaceutical composition, useful for preventing or treating ... Ebola virus...
AT505842
255. Assays for assembly of Ebola Virus Nucleocapsids
ZA200501243
256. SARS AND EBOLA INHIBITORS AND USE THEREOF, AND METHODS FOR THEIR DISCOVERY
WO2008045017
257. IDENTIFICATION OF TWO LINEAR EPITOPES ON EBOLA OR MARBURG VIRUS GLYCOPROTEINS CRITICAL FOR INFECTION
WO2005063798
258. EBOLA PEPTIDES AND IMMUNOGENIC COMPOSITIONS CONTAINING SAME
WO2005023837
259. Immunization for ebola virus infection
US6852324
260. Monoclonal antibodies to Ebola glycoprotein
US6630144
261. Pseudotyped retroviruses
US2006093590
262. Chimeric ebola virus envelopes and uses therefor
US2005255123
263. Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US2004053865
264. IMMUNIZATION FOR EBOLA VIRUS INFECTION
WO9932147
265. Assays for assembly of ebola virus nucleocapsids
US2005180993
266. METHOD OF PREPARING HETEROLOGICAL IMMUNOGLOBULINS FOR VIRAL INFECTIONS MARBURG AND EBOLA CONTROL
RU2089217
267. RECOMBINANT PLASMID DNA pCL1 ENCODING POLYPEPTIDE WITH PROPERTY OF HUMAN LIGHT CHAIN ANTIBODY AGAINST EBOLA VIRUS...
RU2004119372
268. METHOD OF PROPHYLAXIS OF AEROGENIC INFECTIONS CAUSED BY HORSE VENEZUELAN ENCEPHALOMYELITIS, MARBURG AND EBOLA VIRUSES
RU95106890
269. MONOCLONAL ANTIBODY AGAINST RESTON EBOLA VIRUS AND METHOD FOR DETECTING RESTON EBOLA VIRUS USING THE SAME
JP2004315394
270. MONOCLONAL ANTIBODY RECOGNIZING EBOLA VIRUS
JP2002306164
271. Identifying viruses that cause hemorrhagic fever, e.g. Ebola virus...
DE10121214
117 results found in the Worldwide database for:
1. Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
NZ729012
2. USE OF PYRONARIDINE, TILORONE, AND QUINACRINE AGAINST MARBURG VIRUS AND OTHER VIRUS INFECTIONS
US2024009183
3. MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT
RS20220433
4. Primer probe composition for detecting Marburg virus and integrated micro-fluidic chip kit
CN117004765
5. Molecular targets for detecting hemorrhagic fever pathogens and application of molecular targets
CN116987826
6. PREVENTION OF INFECTION BY HIGHLY PATHOGENIC VIRUSES USING TOPICAL APPLICATION OF POVIDONE-IODINE ON MUCOUS MEMBRANES
ZA202109360
7. NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS
US2023339862
8. SESQUITERPENE DERIVATIVE AND USE THEREOF IN PREPARATION OF BROAD-SPECTRUM ANTIVIRAL DRUG
WO2023178740
9. Compositions and methods of manufacturing trivalent filovirus vaccines
GB2619625
10. Broadly neutralizing binding molecules against marburg virus
CN116601169
11. METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS
MY195823
12. EBOLAVIRUS SURFACE GLYCOPROTEIN PEPTIDES, CONJUGATES, AND USES THEREOF
WO2023215784
13. Therapeutic compositions for viral-associated disease states and methods of making and using same
AU2023200800
14. Method For Treating COVID-19 and Related Viral Infections
US2023081431
15. SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES
US2023011571
16. RPA Primer set for recombinase polymerase amplification reaction for detecting Marburg virus and kit comprising the same
KR20220123993
17. Methods and compositions for inducing protective immunity against filovirus infection
NZ730511
18. REPLICATION-DEFICIENT MODIFIED VACCINIA ANKARA (MVA) EXPRESSING MARBURG VIRUS GLYCOPROTEIN (GP) AND MATRIX PROTEIN (VP40)
US2022152190
19. Application of water pteris vittata in prevention and treatment of virus infection
CN114452346
20. FILOVIRUS VACCINES AND METHODS OF USE
US2022080037
21. Application of beta-caryophyllene in prevention and treatment of virus infection
CN114099482
22. Application of water pteris vittata in prevention and treatment of virus infection
CN114099600
23. Application of composition of water pteris vittata and beta-caryophyllene in prevention and treatment of virus infection
CN114099599
24. CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES
US2022064669
25. NICLOSAMIDE FOR THE TREATMENT OF VIRAL DISEASES
WO2022010444
26. POLYMER PREPARATION FOR TREATING VIRUS INFECTION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
CN113811309
27. IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF IMMUNE RESPONSE TO FILOVIRUSES: EBOLAVIRUS AND/OR MARBURGVIRUS, METHOD OF USING IMMUNOBIOLOGICAL AGENT
RU2760439
28. ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS
US2021324051
29. ARYLNAPHTHALENE COMPOUNDS AS VACUOLAR-ATPASE INHIBITORS AND THE USE THEREOF
US2021230149
30. ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION
US2021171521
31. Ebola Virus and Marburg Virus Glycoprotein Mucin-Like Domain Replacement Expression System used as New Vaccine Approaches
US2021069316
32. ARYLNAPHTHALENE COMPOUNDS AS VACUOLAR-ATPASE INHIBITORS AND THE USE THEREOF
US2021032227
33. LNUM- Human Immune Detection System: Human Immune Level Detection and Notification System Using Mobile Phone
AU2020103586
34. REPLICATIVE ADENOVIRUS TYPE 4 VECTOR RECOMBINANT MARBURG VIRUS DISEASE VACCINE
WO2021017135
35. THERAPEUTIC ANTIBODIES TO MARBURG VIRUS
US2020407428
36. Application of small molecular compound in preparation of anti-filamentous-virus drugs
CN112137994
37. MARBURG VIRUS VACCINE WITH HUMAN REPLICATION-DEFICIENT ADENOVIRUS AS VECTOR
US2020392188
38. USE OF PYRIDYLOXYPYRIDINES FOR TREATING INFECTIOUS DISEASES
WO2021097008
39. USE OF PYRIDYLOXYPYRIMIDINES FOR TREATING INFECTIOUS DISEASES
WO2021097002
40. ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF
US2020360397
41. Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
AU2020244499
42. Primers and probes for simultaneous detection of subtypes of Marburg virus and detecting method for Marburg virus using the same
KR20200056347
43. Inhibition Of TCR Signaling With Peptide Variants
US2020123205
44. METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST A MARBURG VIRUS INFECTION
US2020113994
45. METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS
WO2020050852
46. METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS
]US2020048722
47. Monoclonal antibody against filamentous virus GP protein and application of monoclonal antibody
CN110655572
48. COMPOUNDS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS
EA201990021
49. METHOD OF USE OF ERITORAN AS A TLR4 ANTAGONIST FOR TREATMENT OF EBOLA AND MARBURG DISEASE
US2019275067
50. Bis-Benzyl-Tetrahydroisoquinoline Derivatives As Therapeutics For Filovirus
US2019275027
51. METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST A MARBURG VIRUS INFECTION
US2019224301
52. Real-time fluorescent RT-PCR detection method for MARV (Marburg virus)
CN109504808
53. MARBURG MONOCLONAL ANTIBODIES
SG10201806481X
54. HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES
US2018265507
55. Nanoparticle Compositions and Methods Thereof to Restore Vascular Integrity
US2018256509
56. EBOLA/MARBURG VACCINES
US2018243225
57. RNA (Ribonucleic Acid) adapters of anti-viral envelope glycoprotein for inhibiting filovirus infection and application of RNA adapter
CN108330131
58. Marburg virus detection primer, probe and kit
CN107937612
59. 3-N-SUBSTITUTED BORNYL PROPIONATES USED AS MARBURG VIRUS INHIBITORS
RU2649406
60. Method for effectively and specifically inhibiting filoviruses by adopting rhodiola rosea extract
CN107648300
61. ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION
US2017306323
62. RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FILOVIRUS VACCINE
EA201790506
63. Antigen fragment and truncated protamine based on Marburg virus envelope protein and application
CN107022007
64. RPA technology-based marburg virus detection kit and application thereof
CN106636469
65. ANIMAL MODEL FOR EVALUATING FILOVIRUSES
US2017089884
66. Rapid and sensitive method for detection of Marburg virus RT-LAMP
CN105936943
67. METHODS FOR TREATING OR PREVENTING EBOLAVIRUS OR MARBURGVIRUS INFECTIONS
WO2016112072
68. THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS
US2016114022
69. COMPOSITIONS AND METHODS FOR SILENCING MARBURG VIRUS GENE EXPRESSION
US2016076035
70. A NOVEL BROAD-SPECTRUM ANTIVIRAL SYNERGISTIC PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
WO2016025010
71. Preparation and application of hemorrhagic fever associated pathogen identifying gene chip
CN105087824
72. ONE-STEP REAL-TIME RT-PCR METHOD USING PROBE AND PRIMER SETS FOR DETECTION OF EVOLA AND MARBURG VIRUSES
KR20150066859
73. TREATMENT OF EBOLA THROUGH ELECTROMAGNETICALLY CHEMICAL INFUSION, USING A NEWLY ADAPTIVE LANGUAGE OF BIO-SIGNALING CELLULAR COMMUNICATIONS
WO2016097830
74. CONSERVED B CELL EPITOPES OF FILOVIRUS GLYCOPROTEIN AND THEIR USE AS EITHER BIOMARKERS OR THERAPEUTICS AND SUB-UNIT VACCINES FOR EBOLA VIRUS AND MARBURG VIRUS
WO2016079572
75. MAMMALIAN GENES AND GENE PRODUCTS INVOLVED IN INFECTION
WO2013066442
76. SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENT-MARKED PROBES FOR SPECIES-SPECIFIC INSTANT IDENTIFICATION OF MARBURG VIRUS BY POLYMERASE CHAIN REACTION
RU2458143
77. GENERATION OF VIRUS-LIKE PARTICLES AND USE AS PANFILOVIRUS VACCINE
CA2768801
78. INHIBITORS OF FILOVIRUS ENTRY INTO HOST CELLS
US2012189614
79. Vaccine Compositions For Marburg Virus
US2012136142
80. Recombinant proteins from filoviruses and their use
US2012065371
81. C-ABL TYROSINE KINASE INHIBITORS USEFUL FOR INHIBITING FILOVIRUS REPLICATION
WO2012118599
82. Generation of virus-like particles and use as panfilovirus vaccine
US2011280904
83. Fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system
CN102191338
84. Marburg and Ebola dual-virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system
CN102140533
85. Novel Ebola virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system
CN102140532
86. Novel Marburg virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and Marburg virus PCR detection system
CN102140531
87. METHODS OF USE OF ANTIVIRAL COMPOUNDS
US2011065766
88. METHODS OF USE OF ANTIVIRAL COMPOUNDS
US2011065762
89. STRAIN OF HYBRID ANIMAL CELLS Mus musculus L - PRODUCER OF MONOCLONAL ANTIBODIES FOR EXPOSING VP40 PROTEIN OF MARBURG VIRUS
RU2395575
90. STRAIN OF HYBRID ANIMAL CELLS MUS MUSCULUS L3F9 - PRODUCER OF MONOCLONAL ANTIBODIES SUITABLE FOR USE IN "SANDWITCH" IMMUNOENZYMOMETRIC SYSTEM FORMAT FOR DETECTING VP35 PROTEIN OF MARBURG VIRUS ...
RU2393220
91. Generation of virus-like particles and use as panfilovirus vaccines
US2010143409
92. IP-10 BASED IMMUNOLOGICAL MONITORING
EA200970246
93. Optimzed vaccines to provide protection against ebola and other viruses
US2009232841
94. ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION
US2009186849
95. TREATMENT OF HEMORRHAGIC VIRAL INFECTIONS USING A TISSUE FACTOR INHIBITOR
WO2007092607
96. GENERATION OF VIRUS-LIKE PARTICLES AND USE AS PANFILOVIRUS VACCINE
WO2006046963
97. IDENTIFICATION OF TWO LINEAR EPITOPES ON EBOLA OR MARBURG VIRUS GLYCOPROTEINS CRITICAL FOR INFECTION
WO2005063798
98. Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever
US6713069
99. Methods and compositions for use in the treatment of filovirus mediated disease conditions
US2003082517
100. Methods for producing Marburg Virus proteins
US2006251681
101. Composition and method for stimulating immune response to pathogen using complex adenoviral vector
US2004028652
102. Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding
US2004057967
103. Multivalent vaccination using recombinant adenovirus
US2003219458
104. Generation of virus-like particles and use as panfilovirus vaccine
US2006099225
105. Generation of virus-like particles and use as panfilovirus vaccine
US2005266023
106. METHOD FOR PREVENTING AND TREATING A VIRAL CONDITION BY INHIBITING MEMBRANE FUSION
WO9402125
107. METHODS FOR GENE TRANSFER USING PSEUDOTYPED LENTIVIRUSES
WO03035849
108. METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF FILOVIRUS MEDIATED DISEASE CONDITIONS
WO0141784
109. METHOD OF VIRUS "MARBURG" ANTIGEN PREPARING
RU1808013
110. METHOD OF VIRUS "MARBURG" PREPARATION PREPARING
RU1808012
111. METHOD OF VIRUS MARBURG CONCENTRATION FROM SUSPENSION
SU1747485
112. LIQUID PREPARATION CONTAINING IMMUNOGLOBULIN EFFICIENT AGAINST MARBURG FEVER...
RU2003135173
113. STRAIN OF HYBRID CELLS M/N-10G9 OF ANIMAL MUS MUSCULUS L PRODUCING MONOCLONAL ANTIBODIES RAISED TO MARBURG VIRUS
RU2186107
114. RECOMBINANT PLASMID DNA PQ-F35 ENCODING FUSED POLYPEPTIDE F35 SHOWING ANTIGENIC AND IMMUNOGENIC PROPERTIES OF MARBURG VIRUS PROTEIN VP 35
RU2144565
115. METHOD OF PREPARING SERA CONTAINING ANTIBODIES AGAINST MARBURGH VIRUS
RU95107059
116. INHIBITOR OF VIRUS MARBURG REPRODUCTION
RU95102114
117. TROJAN INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
WO03064453